Not provided
Not provided
Not provided
Not provided
Not provided
Loss of funding.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In this research study, the investigators are looking to determine the safety and efficacy of an investigational drug, STA9090 alone and in combination with dutasteride for the treatment of castrate resistant prostate cancer. STA9090 may cause the growth of cancer to slow down or shrink by targeting proteins required for the cancer to grow. The investigators are also looking to determine whether the use of dutasteride to lower male hormone levels will enhance the effect of STA9090 in the treatment of castrate resistant prostate cancer.
Subjects will have a tumor biopsy before treatment begins. Subjects who are randomized to Arm A will receive infusions of STA9090 on days 1, 8, and 15 of a 28 day cycle. Subjects randomized on Arm B will receive daily oral dutasteride for 2 weeks prior to beginning STA9090 treatment. They will continue to receive dutasteride while on study.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| STA9090 with Dutasteride | Experimental | STA9090 with Dutasteride |
|
| STA9090 | Experimental | STA9090 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| STA9090 | Drug | 200 mg/m^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle) |
|
| Measure | Description | Time Frame |
|---|---|---|
| To assess AR transcriptional activity based on expression of a series of AR regulated genes, in baseline and on therapy tumor biopsies in CRPC patients treated with STA- 9090 +/-dutasteride. | The primary objective is to determine whether STA-9090, or the combination with dutasteride further suppresses AR transcriptional activity. AR transcriptional activity will be assessed based on expression of a series of AR regulated genes, in baseline and on therapy tumor biopsies in CRPC patients treated with STA-9090 +/- dutasteride. | 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| To assess the safety and tolerability of STA9090 in men the CRPC | Each type of toxicity rate (a proportion) will be analyzed and summarized descriptively. | 2 years |
| To evaluate progression-free survival (PFS) of men with CRPC treated with STA9090 with or without dutasteride |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Toni K Choueiri, MD | Dana-Farber Cancer Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | United States | ||
| Dana-Farber Cancer Institute |
Not provided
| ID | Term |
|---|---|
| C533237 | STA 9090 |
| D000068538 | Dutasteride |
| ID | Term |
|---|---|
| D001378 | Azasteroids |
| D013260 | Steroids, Heterocyclic |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| STA9090 with Dutasteride | Drug | Dutasteride 3.5 mg orally per day STA9090 200 mg/m^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle) |
|
|
PFS will be summarized using K-M method. |
| 2 years |
| To evaluate the overall survival of men with metastatic CRPC treated with STA9090 alone or in combination with dutasteride | OS will be summarized using K-M method. | 2 years |
| To determine the response rate of measurable disease if present (RECIST) | Patients with measurable disease will be evaluated for response using RECIST criteria and summarized descriptively. | 2 years |
| Boston |
| Massachusetts |
| 02215 |
| United States |
| D011083 |
| Polycyclic Compounds |